Stock comparison
Moderna
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MRNA
Moderna
Market cap
$18.6B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MRNA | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 21F | 69B | MTD |
| Benjamin Graham | 47D | 65B | MTD |
| Philip Fisher | 27F | 63C | MTD |
| Peter Lynch | 4F | 66B | MTD |
| Joel Greenblatt | 2F | 68B | MTD |
| Charlie Munger | 19F | 74B | MTD |
| Terry Smith | 19F | 70B | MTD |
Side-by-side metrics
| Metric | MRNA | MTD |
|---|---|---|
| Market cap | $18.6B | $22.29B |
| P/E (TTM) | - | 25.3x |
| EV/EBIT | - | 21.6x |
| ROIC (TTM) | -37.32% | 36.09% |
| Gross margin | -13.89% | 57.79% |
| Net margin | -143.55% | 21.4% |
| Revenue CAGR 5y | -42.46% | 2.01% |
| EPS CAGR 5y | - | 6.12% |
| Debt / Equity | 0.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MRNA leads on
- EV/EBIT-vs 21.6x+128%
- P/E (TTM)-vs 25.3x+124%
MTD leads on
- ROIC (TTM)36.09%vs -37.32%+197%
- Gross margin57.79%vs -13.89%+124%
- Net margin21.4%vs -143.55%+115%
- Revenue CAGR 5y2.01%vs -42.46%+105%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.